For decades, the food industry has become accustomed to interpreting changes in behavior from cultural movements, demographic transformations, or technological advances. This time, part of that shift began in doctors’ offices and pharmacies and quickly made its way into grocery carts, restaurant menus, and food manufacturers’ research and development centers.
GLP-1 receptor agonist medications, primarily indicated for the treatment of obesity and type 2 diabetes, reduce appetite, increase feelings of fullness, and significantly change the way many consumers relate to food. The effects are already beginning to show up in consumer spending patterns, retail strategies, and investment decisions across a wide range of industries.
For the food industry, what began as a discussion about the growing adoption of a medical treatment has now become a discussion about how quickly it is influencing food choices, reducing consumption volumes, and raising consumers’ nutritional expectations for every meal.
The impact of GLP-1 medications on the food industry can already be measured.
Also read: Artificial intelligence in the food industry: how technology is transforming the sector
GLP-1 medications are reshaping consumption in Brazil
A study conducted by NielsenIQ shows that the effects of so-called “weight-loss injections” extend beyond the clinical setting and are directly reflected in the financial organization of Brazilian households.
The impact begins with the household budget
Among consumers using GLP-1 injectable medications, 84% report a moderate to significant impact on their monthly household budget. To accommodate the treatment within their household budget, 62.2% say they have reduced or postponed other expenses.
The first categories to be affected are those related to dining out and leisure activities. Going out to bars tops the list, with 62.3% of NielsenIQ respondents citing it as an expense they have cut back on. They are followed by spending on miscellaneous services, cited by 56.6% of respondents, restaurants (54.9%), and leisure activities, which 50% of NielsenIQ respondents say they have cut back on.
This finding is noteworthy because it shows that the impact of GLP-1 medications on the food industry does not necessarily begin at the grocery shelf, but rather with the household budget available for dining experiences and food consumption occasions.
The financial reallocation reaches the supermarket
Although only 16.4% of consumers say they have directly reduced their grocery spending, the composition of their shopping baskets changes significantly.
According to NielsenIQ, alcoholic beverages are the category most frequently deprioritized after the start of treatment. They are followed by indulgent products, non-alcoholic beverages, staple food products, personal care items, and household cleaning products.
This redistribution of spending shows that purchasing decisions become more deliberate and selective. Categories traditionally driven by convenience, impulse, or emotional reward are beginning to compete for space with products perceived as delivering greater nutritional value.
Less candy and traditional snacks, more protein and vegetables
The data collected by NielsenIQ helps illustrate the pace of this transformation.
Among GLP-1 users, 76.9% report reducing or eliminating their consumption of chocolate and candy after starting treatment. For snacks and cookies, that figure rises to 73.4%.
Conversely, foods associated with healthy eating are becoming a larger part of consumers’ daily diets. Increased consumption of animal protein was reported by 84.4% of respondents, while 67.6% said they are purchasing more vegetables.
Part of this shift is driven by the reduction in appetite itself. As overall food intake declines, consumers increasingly prioritize foods that deliver greater nutritional value per serving.
A shift that is still small in scale but enormous in potential
The same study shows that injectable GLP-1 medications are still found in only about 5% of Brazilian households.
At the same time, 26% of consumers say they are interested in using this type of treatment but have not yet started because of its high cost or concerns about potential side effects.
The analysis suggests that the impact of GLP-1 medications on the food industry is likely to grow over the coming years, especially as new treatment options enter the market and access to these therapies expands.
Also read: Botanical ingredients: from ancestral roots to modern formulations
What is the consumer profile influenced by GLP-1?
The observed effects go beyond simply reducing food consumption.
Lower intake, higher nutritional requirement
Decreased appetite alters the traditional logic of choosing food. In many cases, consumers begin seeking products that deliver greater nutritional value in smaller portions.
Proteins, fiber, vitamins, and ingredients associated with wellness are taking center stage in purchasing decisions that were once driven primarily by taste and convenience.
Nutrient density is becoming an increasingly important focus in product development strategies.
Digestibility and tolerance are becoming key drivers of consumer choice
The most common side effects experienced by GLP-1 users (nausea, a feeling of fullness, and acid reflux) affect not only how much people eat, but also what they can comfortably tolerate eating.
Lighter, easier-to-digest foods with lower fat content are increasingly preferred, not only for their nutritional benefits but also out of physiological necessity.
For the food industry, this adds a new layer of complexity to product development: products must not only be nutritious, but also well tolerated.
Health, beauty and well-being are also shaping food choices
An analysis published by Veja Negócios shows that the effects of GLP-1 medications extend beyond the food industry, reaching sectors such as healthcare, fashion, beauty, fitness, and wellness.
Physical changes, new daily routines, and greater attention to health indicators are reshaping purchasing habits across multiple categories, reinforcing the emergence of a consumer who is more mindful of the composition and functionality of the products they use every day.
With food, this behavior favors formulations that offer clear, easily understood benefits for consumers.
The impact of GLP-1 medications on the food industry already redefines categories
Few recent trends have placed as much simultaneous pressure on retailers, food manufacturers, and the ingredient supply chain.
The new focus on nutrient density
According to an analysis by Peers Consulting + Technology, the Brazilian market for GLP-1 analogs could reach US$ 9 billion by 2030.
The consultancy notes that reduced calorie intake and the growing demand for more nutritionally efficient foods will require food retailers and manufacturers to adapt quickly.
The conversation is shifting away from how much consumers eat and toward the nutritional quality delivered in every eating occasion.
Protein, fiber, and whole grains gain shelf space
Peers identifies a gradual shift in demand toward products rich in protein, fiber, and whole grains.
Categories associated with digestive health, metabolic support, and muscle maintenance are expected to play an increasingly important role within food product portfolios.
Nutritional supplements, vitamins, and wellness-focused solutions are also gaining momentum as consumers seek to complement diets characterized by lower calorie intake.
What is losing ground in the new consumer landscape
Ultra-processed foods, high-volume indulgent products, and categories that rely heavily on impulse purchases are facing increasing pressure.
The industry’s response to this shift is already beginning to take shape in the products themselves. Manufacturers of snacks, desserts, and convenience foods have been reducing package sizes and individual serving portions. The “eat less, but eat better” mindset is shifting the focus away from volume and toward nutritional quality and the experience delivered in each serving.
This does not mean these categories will disappear. Rather, it underscores the need to redefine their value proposition, rethink portion sizes, and incorporate functional benefits that justify their place in a more selective eating routine.
Also read: Gut health: what’s behind the new generation of beverages and supplements?
Pressure on retail accelerates changes in the industry
Brazil’s GLP-1 market is already worth approximately R$10 billion and continues to expand rapidly.
The battle for shelf space
The pressure on traditional product categories calls for smarter shelf management and more strategic use of retail space.
Health-oriented products, lean proteins, and nutritional solutions are increasingly competing for shelf space traditionally occupied by higher-volume, lower-nutrient-density categories.
The shift in investment toward health and wellness
Market analyses indicate that retailers are increasingly directing investment toward health and wellness, organic foods, and functional nutrition solutions.
At the same time, major pharmacy chains project that GLP-1 treatments could account for as much as 20% of their revenue over the coming years.
Portfolio redesign has begun
In response, the food industry is accelerating product reformulation efforts and the development of entirely new product categories.
Added protein, reduced sugar, higher fiber content, and nutritional fortification are becoming core pillars of product innovation strategies.
What the impact of GLP-1 medications means for food R&D
Research and development teams are now designing for consumers who eat less but expect more from every product.
Reformulation is no longer a differentiator, it’s a necessity
Product portfolios developed for previous consumption patterns may lose their competitive edge as consumers increasingly prioritize nutritional density and functionality.
Product reformulation now extends beyond reducing ingredients of concern to include nutritional enhancement and the creation of greater perceived value for consumers.
Functional and botanical ingredients gain prominence
Functional ingredients and botanicals are taking on a strategic role by enabling the development of foods that align with evolving consumer expectations and emerging market demands.
Growing demand for natural ingredients, scientific validation, and proven functionality is driving interest in solutions that deliver meaningful health benefits while maintaining consistent industrial performance.
Technological performance and sensory experience must go hand in hand.
Higher-nutrient-density formulations often require greater attention to factors such as taste, stability, and performance throughout processing and end-use applications.
Protein fortification can alter formulation properties such as viscosity and solubility, while fibers and botanical extracts may influence attributes such as astringency and the flavor profile of finished products.
For R&D teams, the challenge is not simply to increase the nutritional density of formulations, but to do so without compromising the consumer experience.
Plant proteins, prebiotic fibers, and flavor-masking technologies already make it technically feasible to reduce sugar and fat while maintaining palatability, stability, and industrial performance.
The competitive advantage will belong to companies that successfully combine meaningful functionality with a sensory experience consumers recognize, enjoy, and return to.
Regulatory responsibility in an increasingly scrutinized market
The growing focus on healthier products also increases the food industry’s responsibility for how it communicates product benefits. In Brazil, functional and health claims are subject to specific criteria established by Anvisa and must be supported by scientific evidence and an appropriate regulatory framework before they can be used in food labeling and marketing communications. The agency provides guidelines for evaluating and substantiating these claims and requires evidence supporting the stated effects of ingredients and formulations.
Brazilian regulations permit claims related to the physiological or metabolic role of nutrients and ingredients in the body. However, they do not allow foods or ingredients to be associated with the cure, treatment, or prevention of diseases, nor may therapeutic properties be attributed to food products.
The most promising opportunities are likely to come from formulations that deliver meaningful functionality, consumer-perceived benefits, and differentiation supported by robust scientific and technical evidence. In a market that is becoming increasingly attentive to product composition and the quality of information, credibility is just as important as innovation itself.
An innovation agenda for the next decade
The impact of GLP-1 medications on the food industry builds on trends that have already been gaining momentum in recent years: a growing emphasis on nutrient density, a preference for natural ingredients, increasing demand for functionality, and greater attention to formulation quality.
For the food industry, the question is no longer whether this transformation will happen, but how quickly each company can respond to it.
DR Flavors & Ingredients is supporting this evolution alongside the food industry with functional ingredients, botanical extracts, proteins, fibers, and formulation technologies that enable manufacturers to meet emerging market demands with technical expertise and proven performance.
Follow our blog to stay informed about the trends shaping the future of food, and connect with our specialists to identify new opportunities for your product portfolio.
